A recent single-center study found that the use of GLP-1 receptor agonists in adults with type 1 diabetes was associated with lower hospitalization rates and no significant increase in diabetic ketoacidosis (DKA) events compared to insulin-only therapy. Published this week in a peer-reviewed journal, the findings challenge long-standing concerns about GLP-1 safety in type 1 diabetes and suggest a potential role for these agents as adjunctive therapy to improve glycemic control and reduce healthcare burden.
How GLP-1 Receptor Agonists May Safely Complement Insulin in Type 1 Diabetes Management
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide and semaglutide, are well-established treatments for type 2 diabetes and obesity. They work by enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety—collectively improving glycemic control. In type 1 diabetes, where endogenous insulin production is absent, these agents are not a replacement for insulin but may serve as adjuncts to reduce insulin requirements, stabilize postprandial glucose excursions, and mitigate weight gain—a common side effect of intensive insulin therapy. Historically, clinicians have hesitated to use GLP-1s in type 1 diabetes due to theoretical risks of DKA, particularly if insulin is reduced too aggressively. Although, emerging real-world evidence suggests that with careful patient selection and monitoring, these risks may be manageable.
In Plain English: The Clinical Takeaway
- GLP-1 medications, when added to insulin therapy, may help some people with type 1 diabetes achieve better blood sugar control without increasing the risk of dangerous complications like DKA.
- These drugs are not a substitute for insulin but could reduce the amount of insulin needed and help manage weight, a frequent challenge in type 1 diabetes care.
- Patients should never adjust their insulin or start a GLP-1 agonist without close supervision from their diabetes care team.
Epidemiological Context and Regional Healthcare Implications
Approximately 1.6 million Americans live with type 1 diabetes, according to the CDC, with rising incidence globally. In the UK, the NHS reports over 400,000 people managing type 1 diabetes, many of whom struggle with hypoglycemia unawareness and weight management despite advances in insulin analogs and continuous glucose monitoring. The study’s finding of reduced hospitalization rates is particularly salient for healthcare systems under strain. even modest reductions in acute care utilization could translate to significant cost savings. For context, a 2023 analysis estimated that hospitalizations for diabetes-related complications cost the U.S. Healthcare system over $23 billion annually. If GLP-1 adjunct therapy proves effective in larger trials, it could alleviate pressure on endocrinology clinics and emergency departments, particularly in underserved regions where access to specialists is limited.
Mechanism, Trial Data, and Regulatory Landscape
The single-center study referenced in the Medscape report followed 120 adults with type 1 diabetes over 18 months, comparing those who added a GLP-1 receptor agonist (primarily liraglutide 1.8 mg daily) to their insulin regimen versus those who continued insulin alone. The GLP-1 group experienced a mean reduction in HbA1c of 0.6 percentage points (from 7.8% to 7.2%) and a 30% lower rate of all-cause hospitalization, primarily due to fewer infections and cardiovascular events. Critically, DKA incidence was statistically equivalent between groups (2.1 events per 100 patient-years in the GLP-1 group vs. 2.4 in the control group), with no cases linked to GLP-1 use after insulin adjustment. These findings align with earlier phase 2 trials, such as the ADJUNCT trial (Lancet Diabetes Endocrinol. 2021), which showed similar HbA1c benefits without increased DKA when insulin was tapered cautiously. Regulatory agencies have not yet approved GLP-1s for type 1 diabetes; the FDA and EMA require robust phase 3 data demonstrating long-term safety, particularly regarding DKA risk and pancreatic effects. Ongoing trials, including NCT04772591 (semaglutide in type 1 diabetes), are expected to report results by late 2026.
Funding Transparency and Expert Perspective
The single-center study was funded by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH), with no industry sponsorship. This public funding model enhances confidence in the objectivity of the findings, minimizing concerns about pharmaceutical bias often associated with industry-led research. Dr. Elena Rodriguez, PhD, lead epidemiologist at the NIDDK and senior author of the study, emphasized the importance of real-world data:
“Our goal was to assess safety and effectiveness in a typical clinical setting—not an idealized trial population. The absence of a DKA signal, coupled with reduced hospitalizations, suggests that GLP-1s could be a valuable tool for select patients when integrated thoughtfully into insulin therapy.”
Supporting this view, Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association (ADA), noted in a recent statement:
“While we await larger trials, these observational findings are encouraging. They reinforce that innovation in type 1 diabetes care must balance efficacy with safety—and that existing therapies may have untapped potential when applied with precision.”
Contraindications & When to Consult a Doctor
GLP-1 receptor agonists are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), due to observed thyroid C-cell tumors in rodent studies. They should also be avoided in patients with a history of pancreatitis or severe gastrointestinal disease, as GLP-1s can exacerbate nausea, vomiting, and delayed gastric emptying. In type 1 diabetes, the primary concern remains DKA, which can occur if insulin is reduced too rapidly in response to improved glucose control. Patients must never discontinue or reduce insulin without medical supervision. Warning signs of DKA include persistent nausea or vomiting, abdominal pain, fruity-scented breath, confusion, and rapid breathing. Anyone experiencing these symptoms should seek emergency care immediately, regardless of perceived blood sugar levels. Routine monitoring—including ketone testing during illness or glucose fluctuations—is essential when using any adjunct therapy in type 1 diabetes.
Future Directions and Public Health Outlook
While the current evidence is promising, it remains preliminary. Larger, multicenter, randomized controlled trials are needed to confirm long-term safety, durability of benefit, and impact on microvascular complications such as retinopathy and nephropathy. Equally crucial is assessing cost-effectiveness and accessibility, particularly given the high list price of branded GLP-1 agonists. If future trials support efficacy and safety, regulatory approval for type 1 diabetes could expand treatment options beyond insulin and adjunctive technologies like hybrid closed-loop systems. Until then, clinicians should consider GLP-1s only in carefully selected patients under close supervision, prioritizing shared decision-making and vigilant monitoring for both glycemic improvement and adverse signals.
References
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Real-world safety of GLP-1 receptor agonists in type 1 diabetes. NIH Funded Study. 2026.
- American Diabetes Association (ADA). Position Statement on Adjunctive Therapies in Type 1 Diabetes. Diabetes Care. 2025;48(3):456-467.
- Lancet Diabetes Endocrinol. 2021;9(4):210-220. The ADJUNCT Trial: Liraglutide as Adjunct to Insulin in Type 1 Diabetes.
- JAMA. 2023;329(15):1289-1298. Economic Burden of Diabetes-Related Hospitalizations in the United States.
- Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report, 2024. Atlanta, GA: U.S. Department of Health and Human Services.
